Business as usual at the FDA

After a 14-day delay in posting my response to the glutamate industry’s criticism of FDA-2021-P-0267, which is part of a four-pronged thrust at having the GRAS status of monosodium glutamate (MSG) withdrawn, my response to the glutamate industry has finally been “found” and posted.

“Found” is the key word here. I’ll be back to share the details of this latest example of FDA/glutamate-industry cooperation as soon as time allows.

Adrienne